Overrated / Underrated.
One vote in each column. The clock resets at the start of every quarter — see what the community thinks is hype and what's quietly working.
The biohack you think is the most overhyped right now.
The biohack the loudest voices ignore.
What's the most overrated biohack right now?+
The leaderboard updates live as the community votes. Recurring contenders across quarters: high-dose NMN/NR (NAD+ rises but outcome data thin), CGMs for non-diabetic healthy adults (signal often swamped by noise), red-light therapy panels (works only for narrow indications with clinical data — most marketing oversells), and "longevity" multivitamins with no specific mechanism story.
What's the most underrated biohack?+
Same caveat — live leaderboard. Items that consistently show up: strength training (mortality protection rivals any drug), sleep regularity (matters as much as duration), magnesium glycinate, dental hygiene (periodontal disease is a real ApoB-independent cardiovascular risk), and just walking. Boring, free, hard to monetize, so they get less airtime than the expensive supplement of the month.
Why does the poll reset every quarter?+
Hype cycles in biohacking move fast — what looked promising six months ago can have failed RCT replications by now, and new categories emerge constantly. Quarterly resets keep the leaderboard reflecting current consensus rather than freezing the early-adopter takes.
How do you actually evaluate whether a biohack works?+
Look for outcome data, not biomarker data. "It raises X in your blood" is mechanism; "it reduces all-cause mortality by Y% in a cohort of Z people" is outcome. Most overrated items have the first and lack the second. The cheapest filter: search the intervention + "meta-analysis" + "human" on PubMed before buying.
Can I see past quarters' results?+
Past quarters are stored in the database but not yet surfaced in the UI. The current quarter's vote is what's visible; archive UI is coming.
How to spot an overrated biohack
Most biohacks that turn out to be overrated share a pattern: a strong mechanistic story, an early animal or small-N human result, and a viral podcast moment — followed by larger RCTs that fail to replicate the effect size. The current cycle examples include high-dose NR/NMN (NAD+ rises, downstream effects modest in humans so far), continuous glucose monitors for healthy non-diabetics (signal swamped by measurement noise), and many red-light therapy claims outside of the very narrow indications with clinical data.
The cheapest filter: look for outcome data, not biomarker data. If the only evidence is 'it raises X in your blood,' the intervention may still be worth doing but it isn't proven to do what the marketing implies.
How to spot an underrated one
The mirror image: cheap, ancient, behaviorally boring interventions with large and consistent outcome effects that get less airtime because there's no product to sell. Strength training, walking, sleep regularity (not just duration), magnesium glycinate for the magnesium-deficient, and dental hygiene (periodontal disease is a real ApoB-independent cardiovascular risk factor) all qualify.
See how you compare.
Get the weekly research drop — what the audience actually does, plus the protocols I'm testing on myself. No spam, unsubscribe anytime.